---
title: "广东泰恩康医药股份有限公司 (301263.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301263.SZ.md"
symbol: "301263.SZ"
name: "广东泰恩康医药股份有限公司"
industry: "制药"
---

# 广东泰恩康医药股份有限公司 (301263.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.tai-kang.com.cn](https://www.tai-kang.com.cn) |

## Company Profile

公司，成立于 1999 年，历经二十余年的稳健发展，已成为一家集研发、生产、销售于一体的综合性医药创新企业。公司始终秉持 “创新技术，引领健康” 的企业使命，通过药品自主研发和强化品牌建设，构建了涵盖医药产品、医疗器械、医药技术服务与转让等多元化的业务生态体系。公司聚焦于挖掘具有临床价值、差异化的产品，目前公司已形成两性健康用药、肠胃用药、眼科用药三大优势板块，公司产品为盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片;和胃整肠丸;沃丽汀;风油精、米诺地尔搽剂、六味地黄丸、红花油、驱风油、薄荷通吸入剂、香荷止痒软膏、复方醋酸地塞米松乳膏、复方酮康唑乳膏、复方酮康唑发用洗剂、藿香正气丸、逍遥丸、...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:09.000Z

**Overall: C (0.52)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 96 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.31% |  |
| Net Profit YoY | -82.71% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 7.83 |  |
| Dividend Ratio | 0.62% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13.57B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 673.80M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.33% | C |
| Profit Margin | 3.45% | C |
| Gross Margin | 58.82% | B |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -10.31% | D |
| Net Profit YoY | -82.71% | E |
| Total Assets YoY | 5.30% | B |
| Net Assets YoY | -0.85% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 2896.08% | A |
| OCF YoY | -10.31% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.29 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 24.84% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 广东泰恩康医药股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.33%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "3.45%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "58.82%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-10.31%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-82.71%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "5.30%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.85%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "2896.08%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-10.31%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.29",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "24.84%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 583.17 | 156/222 | 528.00 | 186.81 | 93.22 |
| PB | 7.83 | 201/222 | 8.56 | 7.50 | 4.94 |
| PS (TTM) | 20.14 | 209/222 | 21.73 | 19.31 | 12.27 |
| Dividend Yield | 0.62% | 121/222 | 1.44% | 0.65% | 0.56% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-02-24T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 31.92 |

## References

- [Company Overview](https://longbridge.com/en/quote/301263.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301263.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301263.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.